MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Milestone Pharmaceuticals (MIST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The recent FDA approval of Cardamyst, strong analyst upgrades with a price target of $8 (significantly higher than the current pre-market price of $1.72), and positive sentiment around the commercial potential of Cardamyst make this stock a compelling opportunity. Although technical indicators show a neutral to slightly bearish short-term trend, the long-term potential outweighs these concerns.
The MACD is negative and expanding, indicating bearish momentum. RSI is at 29.34, suggesting the stock is nearing oversold territory. Moving averages are converging, showing indecision. Key support is at $1.731, and resistance is at $1.975. Short-term technicals are neutral to slightly bearish.
FDA approval of Cardamyst with a clean label and no market-limiting warnings.
Analysts have raised price targets to $8, citing strong commercial potential and upcoming launch.
Positive sentiment from analysts regarding Cardamyst's market opportunity and management's strategy.
Technical indicators suggest short-term bearish momentum.
No significant hedge fund or insider trading activity to support immediate upside.
Financial performance shows negative net income and declining EPS.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of $11.92M, though this represents a 26.31% improvement YoY. EPS declined by 14.29% to -0.12. Financials are weak but improving.
Analysts are overwhelmingly positive, with multiple upgrades and price target increases to $8. They cite the commercial potential of Cardamyst and management's strategic execution as key drivers for future growth.
